PDF factsheet
      Z

antiplatelets drug in CABG surgery for all type of patients, clinical trials results

aspirin versus placebo
McEnany, 1982
aspirin 1200
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 22m
Lorenz, 1984
aspirin 100 mg/d
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 4m
GESIC (aspirin), 1990
aspirin 150 mg daily
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 28d
Sydney, 1991
aspirin 324 mg daily
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 12m
Hockings, 1993
aspirin 100
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 6m
aspirin + dipyridamol versus control
Pantely, 1979
aspirin 325 mg three times a day + dipyridamole 75 mg three times a day
versus
control
patients undergoing aortocoronary saphenous-vein bypass-graft surgeryopen
Follow-up duration: 6m
Brussels, 1987
aspirin 200 + dipiridamol 400 (H)
versus

Follow-up duration: 12m
Czech, 1986
aspirin 1000 + dipiridamol 225
versus
control (no medication)
Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less open
Follow-up duration: 12m
Des Moines, 1980
aspirin 20 + dipiridamol 100
versus

Follow-up duration: 12m
aspirin + dipyridamol versus placebo
GESIC (aspirin+dipyridamol), 1990
aspirin 50 mg + dipyridamole 75mg 3 times daily
versus
placebo
patients undergoing CABG double blind
Follow-up duration: 28d
Spain
Brooks, 1985
aspirin 990 mg and dipyridamole 225 mg daily
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 12m
Mayo-A, 1984
aspirin 975 + dipiridamol 225
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 12m
Wadsworth, 1985
aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d
versus
placebo
coronary bypass patients double blind
Follow-up duration: 12m
Basel, 1989
aspirin 50 + dipiridamol 400
versus
placebo
patients who had aortocoronary vein bypass surgery double blind
Follow-up duration: 9m
Leeds-B, 1985
aspirin 990 + dipiridamol 225 (W)
versus
placebo
patients undergoing aorta-coronary bypass grafting for disabling anginadouble blind
Follow-up duration: 6m
Thaulow, 1987
aspirin 975 + dipiridamol 225
versus
placebo
Patients scheduled to receive at least three aortocoronary venous bypass grafts double blind
Follow-up duration: 3m
clopidogrel+aspirin versus aspirin
CASCADE, 2009
NCT00228423
aspirin 162 mg plus clopidogrel 75 mg daily for 1 year
versus
aspirin 162 mg plus placebo daily
patients after CABG involving at least two saphenous vein graftsdouble blind
Follow-up duration: 1 y
dipyridamol versus control
Toronto dipyridamole, 1987
dipiridamol 400
versus
control
patients undergoing elective coronary artery bypass grafting
Follow-up duration: 48h
dipyridamol versus placebo
Ekestrom, 1990
dipiridamol 100 mg orally q.i.d.
versus
placebo
patients undergoing coronary bypass surgerydouble blind
Follow-up duration: 12m
sulfinpyrazone versus placebo
Baur, 1982
sulfinpyrazone 800 mg/day
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 10d
sulotroban versus control
German sulotroban, 1989
ST
versus

Follow-up duration: 21d
ticlopidine versus control
Zurich, 1982
ticlopidine 500 (NC)
versus

Follow-up duration: 3m
Knudsen-B, 1983
ticlopidine 500
versus

Follow-up duration: 6m
Romeo, 1983
ticlopidine 500
versus

Follow-up duration: 3m (12m)
Kohn, 1990
ticlopidine 500
versus

Follow-up duration: 14d
ticlopidine versus placebo
Liège-I, 1984
ticlopidine 250 mg twice daily
versus
placebo
patients undergoing aortocoronary bypass graft proceduresdouble blind
Follow-up duration: 3m
Liège-II, 1987
ticlopidine 250 mg twice daily
versus
placebo
patients undergoing venous coronary artery bypass grafting double blind
Follow-up duration: 12m
various versus placebo
Guiteras, 1989
aspirin 150 + dipiridamol 225, dipiridamol 225 + trifusal 900
versus
placebo
patients undergoing coronary bypass graftingdouble blind
Follow-up duration: 7m
VA Co-op CABG, 1988
aspirin 325 daily, aspirin 325 three times daily, sulfinpyrazone, aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
versus
placebo
patients undergoing CABGdouble blind
Follow-up duration: 12m

  Options


in first

in second

  Filter